openPR Logo
Press release

Parkinson's Disease Pipeline, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

04-18-2024 04:00 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Parkinsons Disease Pipeline

Parkinsons Disease Pipeline

DelveInsight's, "Parkinson's Disease Pipeline Insight 2024" report provides comprehensive insights about 140+ Parkinson's Disease companies and 150+ pipeline drugs in Parkinson's Disease pipeline landscape. It covers the Parkinson's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Parkinson's Disease Pipeline Report
• DelveInsight's Parkinson's Disease pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Parkinson's Disease treatment.
• The leading Parkinson's Disease companies working in the market include Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
• Promising Parkinson's Disease Pipeline Therapies in the various stages of development include BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others.
• April 2024:- Biogen- A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease. In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD).
• April 2024:- Hoffmann-La Roche- A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 6-Year All-Participants-on-Treatment Extension. The study will consist of three parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2).

Request a sample and discover the recent advances in Parkinson's Disease Treatment Drugs @ Parkinson's Disease Pipeline Outlook Report- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Parkinson's Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson's disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Parkinson's Disease Overview
Parkinson's disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine.

Find out more about Parkinson's Disease Treatment Landscape @ Drugs for Parkinson's Disease Treatment- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson's Disease Emerging Drugs Profile
• Tavapadon: Cerevel Therapeutics
• IkT-148009: Inhibikase Therapeutics
• NLY01: Neuraly
• PT320: Peptron

Parkinson's Disease Pipeline Therapeutics Assessment
There are approx. 140+ key Parkinson's Disease companies which are developing the Parkinson's Disease therapies. The Parkinson's Disease companies which have their Parkinson's disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics.

DelveInsight's Parkinson's Disease pipeline report covers around 150+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Parkinson's disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Parkinson's Disease Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Parkinson's Disease Pipeline Therapies @ Parkinson's Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Parkinson's Disease Pipeline Report
• Coverage- Global
• Parkinson's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Parkinson's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Parkinson's Disease Companies- Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
• Parkinson's Disease Pipeline Therapies- BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others.

Dive deep into rich insights for new drugs for Parkinson's Disease treatment, Visit @ Parkinson's Disease Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Parkinson's Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Parkinson's Disease - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tavapadon: Cerevel Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Prasinezumab : Roche
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MEDI1341: AstraZeneca
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Neural microtissues: Treefrog Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Parkinson's Disease Companies
21. Parkinson's Disease Products
22. Parkinson's Disease Unmet Needs
23. Parkinson's Disease Market Drivers and Barriers
24. Parkinson's Disease Future Perspectives and Conclusion
25. Parkinson's Disease Analyst Views
26. Parkinson's Disease Companies
27. Appendix

For further information on the Parkinson's Disease pipeline therapeutics, reach out to Parkinson's Disease Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Published Links-
https://www.hoyolab.com/article/27093025
https://www.kfz-betrieb.vogel.de/community/user/ybhardwaj
https://pad.funkwhale.audio/s/z1sjb2E6Z
https://swaay.com/u/daviddollareusa/about/
https://www.bestadsontv.com/profile/462518/Denny-Dones
https://manybooks.net/user/denny-dones
https://topbazz.com/germanydennydones
https://wibki.com/dennydones1
https://onlineghibli.com/tavern/members.php?mode=profile&userid=12548&boardid=1
https://www.undrtone.com/germanydennydon
https://solo.to/germanydennydones
https://app.geniusu.com/users/2455075
https://forum.alidropship.com/members/germanydennydones.50354/#about
https://pantip.com/profile/7306022#topics
https://pubhtml5.com/homepage/npvs/preview
https://doodleordie.com/profile/germanydennydones
https://www.rafabasa.com/author/germanydennydones/
https://www.tabletennisdaily.com/forum/members/germanydennydones.122613/#about
https://nhattao.com/members/user6331540.6331540/
https://thelittlenet.com/dennydonesgerman
http://demo.advised360.com/read-blog/154799
https://thehealthbridges.com/read-blog/19127
https://app.talkshoe.com/user/joneswilliam/about#google_vignette
https://www.vaca-ps.org/blogs/142022/The-Evolving-Landscape-of-Healthcare-Business-Consulting-Services
https://www.anobii.com/en/01d38d0b9694756e64/profile/activity
https://myanimelist.net/profile/dennydonesgerman
https://forum.pivx.org/threads/healthcare-business-consulting-services-navigating-complexity-in-modern-healthcare.2035/
https://pubhtml5.com/homepage/npvs/
https://b31.org.uk/author/anniesmith9/
https://fairygodboss.com/users/profile/Ix-vMa09gj/Annie-Smith
https://forum.completefrance.com/index.php?/topic/71194-key-areas-of-focus-in-healthcare-consulting-services/
https://educatorpages.com/site/kelleadvin/pages/blog?
https://offgridworld.com/author/anniejones9/
https://www.openhumans.org/member/me/
https://findpenguins.com/5zphebtv0zouo
http://jobs.emiogp.com/author/williamsmith9/
https://www.shippingexplorer.net/en/user/williamsmith9/88249
https://wakelet.com/@DennyDones813
https://startupxplore.com/en/person/denny-dones
https://www.nfpjobs.com.au/employers/1939365-delveinsight
https://community.hodinkee.com/members/dennydoness
https://jobs.mikeroweworks.org/employers/1930150-delveinsight
https://www.social-vape.com/read-blog/132516
https://codex.core77.com/users/dennydones9
https://www.newjerseyhunter.com/members/dennydones1.84566/#about
https://au.blurb.com/user/dennydones9?profile_preview=true
https://trabajo.merca20.com/author/kelleadvin/
https://www.atlasobscura.com/users/dennydones1
https://www.mixcloud.com/dennydones1/
https://www.designspiration.com/ybhardwaj/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Parkinson's Disease Pipeline, FDA Approvals, Clinical Trials and Companies 2024 (Updated) here

News-ID: 3468938 • Views:

More Releases from DelveInsight Business Research LLP

Addison's Disease Market Outlook Report 2032 |Akorn Operating Co., Amneal Pharmaceuticals Inc., Bristol Myers Squibb Co., Neurocrine Biosciences Inc., Hikma Pharmaceuticals Plc., Merck & Co., Novartis AG., Pfizer Inc
Addison's Disease Market Outlook Report 2032 |Akorn Operating Co., Amneal Pharma …
DelveInsight's "Addison's Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Addison's Disease, historical and forecasted epidemiology as well as the Addison's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Addison's Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Addison's Disease market size
Anemia In Chronic Kidney Disease Market Outlook Report 2032 | 3SBio, UBI Pharma and Disc Medicine
Anemia In Chronic Kidney Disease Market Outlook Report 2032 | 3SBio, UBI Pharma …
DelveInsight's "Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Anemia In Chronic Kidney Disease, historical and forecasted epidemiology as well as the Anemia In Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Anemia In Chronic Kidney Disease market report provides current treatment practices, emerging drugs, the market share of
Visceral Pain associated with GI disorders Market Outlook Report 2032 | Addex Therapeutics Ltd., AstraZeneca., Astellas Pharma, Allergan, Chromocell Corporation, Takeda, GIcare Pharma, AbbVie, Grunenthal GmbH
Visceral Pain associated with GI disorders Market Outlook Report 2032 | Addex Th …
DelveInsight's "Visceral Pain associated with GI disorders Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Visceral Pain associated with GI disorders, historical and forecasted epidemiology as well as the Visceral Pain associated with GI disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Visceral Pain associated with GI disorders market report provides current treatment practices, emerging drugs,
Glabellar Frown Lines Market Report Outlook 2032 | Allergan, Galderma, Merz Pharmaceuticals, Evolus, Revance Therapeutics, Hugel Inc.
Glabellar Frown Lines Market Report Outlook 2032 | Allergan, Galderma, Merz Phar …
DelveInsight's "Glabellar Frown Lines Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Glabellar Frown Lines, historical and forecasted epidemiology as well as the Glabellar Frown Lines market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Glabellar Frown Lines market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted

All 5 Releases


More Releases for Parkinson

QualitySolicitors Parkinson Wright invest in the future
QualitySolicitors Parkinson Wright has selected Liberate from Linetime as its business-wide legal services software platform. The Worcestershire based practice, with over 100 staff, operate from 4 offices and have a highly regarded reputation for their services including residential property, private client, family, dispute resolution and commercial. The firm also has its own estate agency. The firm recognised that to continue delivering high quality services to its clients it needed to provide
Wolff Parkinson White syndrome Market found Future opportunities of 2023
The Analysis presents the study of Global Wolff Parkinson White syndrome Market facilitating the regional and country wise analysis covering the strategic analysis of each market player and the market share they hold Wolff Parkinson White Syndrome Market Information: By Types (Type A, Type B) By Diagnosis (Electrocardiogram (ECG), Electrophysiological Testing, Others) By Treatment (Drugs (Anti-Arrhythmic, Beta-Blockers, Others), Cardioversion, Radiofrequency Catheter Ablation, Surgery, Artificial Pacemaker, Others) By End Users - Global
PARKINSON RESEARCH FOUNDATION Announces Director of Patient Programs, Services a …
The Parkinson Research Foundation is pleased to announce that Marilyn Tait has joined the foundation as the Director of Patient Programs, Services and Advocacy. Tait, is a graduate of Thomas Jefferson University School of Nursing in Philadelphia, Pennsylvania. Tait has forty years experience in healthcare marketing and program development. After specializing in oncology for 30 years, Tait embarked on her new career at a time in her life when
PARKINSON RESEARCH FOUNDATION’S (PRF) WESTERN CARIBBEAN FOURTH EDUCATIONAL CRU …
The Parkinson Research Foundation (PRF), a non-profit organization with a dedicated patient education program, will return to the Western Caribbean for its fourth educational cruise. PRF developed its educational cruise program to give Parkinson patients, caregivers family and loved ones unrivaled access to experts in the movement-disorder field. After visiting the Bahamas and Alaska on the first two respective PRF cruises, PRF’s ventured to the Western Caribbean on its most
PARKINSON RESEARCH FOUNDATION (PRF) Develops New Patient Outreach Program
One of the principal missions of the Parkinson Research Foundation (PRF) that distinguishes it from other Parkinson organizations is PRF’s focus on patient education; specifically education that enables Parkinson patients and their caregivers to live fuller and more comfortable lives with Parkinson's disease. The Foundation’s educational events, including educational cruises, gather leading Parkinson experts, therapists and nutritionists from across the country to offer life-changing tools and knowledge for individuals affected
Parkinson`s Disease:New Hope Educational Conference
PARKINSON’S DISEASE: NEW HOPE EDUCATIONAL CONFERENCE Become knowledgeable about the advancements in surgery The Parkinson Research Foundation is proud to announce that Dr. James Schumacher will be speaking about advances in surgery at our fourth annual New Hope for Parkinson’s conference on November 1st in Boca Raton. Dr. Schumacher is an internationally known expert in the field of neurosurgical treatment of Parkinson’s disease and movement disorders. He has an extensive background and